作者
Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep Maria Piulats, Karim Fizazi, Axel S Merseburger, Celestia S Higano, Laurence E Krieger, Charles J Ryan, Felix Y Feng, Andrew D Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P Watkins, Tony Golsorkhi, Simon Chowdhury
发表日期
2020/6/1
期刊
Clinical Cancer Research
卷号
26
期号
11
页码范围
2487-2496
出版商
American Association for Cancer Research
简介
Purpose
Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations.
Patients and Methods
TRITON2 enrolled patients who had progressed on one or two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Key endpoints were investigator-assessed radiographic response per modified RECIST/PCWG3 and PSA response (≥50% decrease from baseline).
Results
TRITON2 enrolled 78 patients with a non-BRCA DDR gene alteration [ATM (n = 49), CDK12 (n = 15), CHEK2 (n = 12), and other DDR genes (n = 14)]. Among patients …
学术搜索中的文章
W Abida, D Campbell, A Patnaik, JD Shapiro, B Sautois… - Clinical Cancer Research, 2020